Cardio Diagnostics Holdings (NASDAQ: CDIO), a company specializing in AI-powered precision cardiovascular medicine, announced on June 25, 2026, that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for its Epi+Gen CHD and PrecisionCHD tests. The tests, which are physician-ordered blood tests, will be available to eligible members with prior authorization, broadening access to advanced coronary heart disease assessment and personalized treatment planning.
The Epi+Gen CHD test evaluates a patient's three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, according to Cardio Diagnostics. This coverage decision marks a step toward integrating precision cardiovascular medicine into community healthcare networks, potentially improving early detection and management of heart disease.
Cardio Diagnostics emphasizes that its technology leverages a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine to make cardiovascular disease prevention, detection, and management more accessible and personalized. The company aims to become a leading medical technology firm for improving outcomes in cardiovascular disease. For more details, the full press release is available at https://nnw.fm/EFQen.
This coverage expansion is significant as it brings advanced diagnostic tools to a broader patient population, potentially reducing the burden of coronary heart disease, a leading cause of death worldwide. By integrating these tests into managed care, Atlas Healthcare Physicians may enhance risk stratification and treatment decisions for their members. However, the company cautions that forward-looking statements involve risks and uncertainties, as detailed in its SEC filings. More information about Cardio Diagnostics and updates relating to CDIO can be found in the company's newsroom at https://ibn.fm/CDIO.
